Ultragenyx Pharmaceutical, Inc.

FGIM primarily provides advice with respect to equity investment strategies; however, they do not recommend a particular type of security. The firm is a multi strategy investor that manages portfolios of equity and fixed-income investments for institutional and private clients. Their strategies include core international/emerging market equities; international equity; international small- and mid-cap equity; balanced/asset allocation; managed risk and the Kaufmann Accounts. The Kauffman strategy invests in small, mid or large cap stocks, utilizing a fundamental bottom-up process seeking growth companies and may invest in less developed or emerging markets.

Alkeon Capital Management invests principally, but not solely, in long or short positions of publicly-traded and private companies in global markets on behalf of the funds it manages. They provides advisory or sub-advisory services to its clients using the general strategy except that (a) the Alkeon Growth Funds, the OAM Funds, ALPRO Growth, MS UCITs and the Insurance Series primarily invest in long and short positions of global growth stocks; (b) the Alkeon Select Funds and the Alkeon Capital Partners Fund invest primarily in long positions of global growth stocks; and (c) the Alkeon Asia Growth Funds invest primarily in long and short positions of global growth stocks based in the Asia Pacific region. Alkeon Capital Management employs a bottom-up, fundamentally driven, research-intensive approach to investing. On the long side, their investment program focuses on investing in the equity securities of companies that Alkeon believes are well positioned to benefit from demand for their products or services, including companies that can innovate or grow rapidly relative to their peers in their markets. On the short side, Alkeon Capital Management may affect short sales of securities when it believes that the market price of a security is above its estimated intrinsic or fundamental value. This analytical process involves the use of valuation models, review and analysis of published research, and, in some cases, discussions with industry experts and company visits. Alkeon also takes into account economic and market conditions.

OrbiMed Advisors focuses on investments in the global healthcare industry. They utilizes strategies based on evaluating pharmaceutical, biotechnology, medical device, healthcare services and other companies in the global healthcare sector. The instruments in which OrbiMed invests include US and non-US equities, both long and short, as well as privately placed securities, debt securities, royalty bonds and other royalty instruments, currencies, private investments in public equity securities (PIPEs), ETFs, index options, and derivatives (including swap agreements). The firm invests across the global healthcare industry, from seed-stage venture capital to large publicly-traded companies. Investments are made across three strategies: public equity, private equity, and royalty opportunities. OrbiMed Advisors manages a series of public equity funds, including long/short event-driven funds and closed-end investment trusts. They invest across all types of publicly-traded companies, from biopharmaceuticals to medical devices and healthcare services worldwide. OrbiMed's private equity strategy is broad and flexible, investing from start-ups through growth equity. OrbiMed is typically a lead investor, seeking to help build our portfolio companies. Their geographic focus includes North America, Asia, Europe and Israel. For Royal Opportunities strategy, OrbiMed provides commercial-stage healthcare companies with non-dilutive structured debt capital. Additionally, they can monetize royalty streams, providing valuable financing solutions to owners of intellectual property.

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

TPG Biotech is a life science venture capital platform of TPG Capital. TPG Biotech focuses on therapeutics, medical devices, and healthcare services. By leveraging TPG''s global network to support portfolio companies, TPG Biotech provides access to opportunities and operational experts from other platforms. They target investments globally with a particular focus on opportunities in North America & Asia Pacific, and provides financing for early & later stage capital requirements.

Impresa focuses on early-stage investments in start-up companies across US and International portfolio companies. There fund focuses on companies operating in the fields of biopharmaceutical, medical technology & healthcare IT and services.There funds are larger and more global. In the US and Europe, they are F-Prime Capital investing in healthcare (formerly Fidelity Biosciences) and in technology (formerly part of Devonshire Investors). In other geographies, there sister fund is called Eight Roads (formerly Fidelity Growth Partners), with investment teams in London, Shanghai, Beijing, Hong Kong, Tokyo, and Mumbai with over $2 trillion in assets under management.